Make Informed Investment Decisions with Affordable Access to Experts
Exploring the market potential of Madrigal's MGL-3196 for the treatment of heterozygous Familial Hypercholesterolemia (HeFH)Ticker(s): MDGL
Name: Dr Michael D. Shapiro - D.O.
Institution: Oregon Health & Science University
- Associate Director of the Center for Preventive Cardiology and Professor at Oregon Health & Science University with a specific clinical focus on inherited lipid disorders.
- Personally manages ~500 patients with HeFH within the center for Preventive Cardiology.
- Research focuses on PCSK9 physiology and its impact on lipoprotein metabolism; engaged in clinical trials testing novel lipid modulating therapeutics.
Please describe your clinical practice; how many patients with HeFH do you currently manage?Added By: c_admin
What are your initial thoughts on the recent results from the Phase 2 HeFH trial of MGL-3196?Added By: c_admin
On a scale of 1-10 (10 being extremely excited), how would you rate your level of excitement for this drug?Added By: c_admin
Are there any other therapies in the HeFH space that look very promising to you right now?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.